RxDoctor Payments Data

Luis Geada, MD

Internal Medicine · Miami, FLNPI 1649236837

Payments from drug & device makers

$1,722in general payments, 2019–2025

Across 35 payments — averaging $49.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$553
  • Acell, Inc.$371
  • AstraZeneca$221
  • Medtronic$121
  • Intercept Pharmaceuticals, Inc.$114
  • KARL Storz Endoscopy-america$105
  • plus $238 from 9 others

What the payments were for

  • Travel & lodging$21613%
  • Food & beverage$1,50787%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,722 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$14,901
Medicare patients
37
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$62,251
JanuviaSitagliptin Phosphate35$40,039
MounjaroTirzepatide23$24,692
FarxigaDapagliflozin Propanediol24$23,228
Tresiba Flextouch U-200Insulin Degludec16$22,453
JanumetSitagliptin Phos/Metformin Hcl14$20,423
OzempicSemaglutide19$18,638
MyrbetriqMirabegron27$17,897
XareltoRivaroxaban12$10,412
VascepaIcosapent Ethyl11$9,720
SymbicortBudesonide/Formoterol Fumarate19$6,363
Advair DiskusFluticasone Propion/Salmeterol11$5,376
SynthroidLevothyroxine Sodium51$5,348
Omeprazole217$4,857
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$62,25156 claims
AstraZenecaFarxiga, Symbicort$221$29,59143 claims
Lilly USA, LLCMounjaro$16$24,69223 claims
Novo NordiskOzempic$56$18,63819 claims
Johnson & JohnsonXarelto$21$10,41212 claims
AbbVieSynthroid$553$5,34851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →